Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879887 | 1.00 | UGT2B7 (0.33) | UGT2B7PLA2G2AAPLNRCYP3A4MAPT | |
| SCHEMBL14879886 | 1.00 | UGT2B7 (0.33) | UGT2B7PLA2G2AAPLNRCYP3A4MAPT | |
| SCHEMBL14879985 | 0.80 | — | — | |
| SCHEMBL14879952 | 0.76 | CYP3A4 (0.35) | CYP3A4MAPTRECQL | |
| SCHEMBL18237168 | 0.76 | CYP3A4 (0.35) | CYP3A4MAPTRECQL | |
| SCHEMBL15874272 | 0.72 | CYP3A4 (0.36) | CYP3A4MAPTRECQL | |
| SCHEMBL14879850 | 0.69 | SMN1; SMN2 (0.37) | MAPT | |
| SCHEMBL15874150 | 0.68 | — | — | |
| SCHEMBL16010886 | 0.67 | CHRNB2 (0.39) | — | |
| SCHEMBL14879868 | 0.67 | CHRNB2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | UGT2B7 3156/4885PLA2G2A 558/4885APLNR 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.